Tango Therapeutics, Inc. (TNGX)
9.40
+0.30
(+3.30%)
USD |
NASDAQ |
Dec 12, 11:05
Tango Therapeutics Cash from Investing (Quarterly): 47.48M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| XOMA Royalty Corp. | 58.21M |
| Viking Therapeutics, Inc. | 160.02M |
| Avanos Medical, Inc. | -31.50M |
| Krystal Biotech, Inc. | -4.286M |
| Moderna, Inc. | 700.00M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -30.95M |
| Cash from Financing (Quarterly) | 2.541M |
| Free Cash Flow | -146.76M |
| Free Cash Flow Per Share (Quarterly) | -0.2803 |
| Free Cash Flow to Equity (Quarterly) | -30.86M |
| Free Cash Flow to Firm (Quarterly) | -31.10M |
| Free Cash Flow Yield | -14.18% |